日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials

一线 Cemiplimab 治疗局部晚期非小细胞肺癌:EMPOWER-Lung 1 和 EMPOWER-Lung 3 试验的最新亚组分析

Kalinka, Ewa; Bondarenko, Igor; Gogishvili, Miranda; Melkadze, Tamar; Baramidze, Ana; Sezer, Ahmet; Makharadze, Tamta; Kilickap, Saadettin; Gümüş, Mahmut; Penkov, Konstantin; Giorgadze, Davit; Özgüroğlu, Mustafa; Quek, Ruben G W; McIntyre, Debra A G; Kim, Eric; Seebach, Frank; Pouliot, Jean-Francois

The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

晚期肺癌免疫治疗患者肺部免疫预后指数早期变化的预后意义

Cengiz, Muhammet; Bozkurt, Oktay; Nuransoy Cengiz, Ayşe; Inanc, Mevlude; Ozkan, Metin; Mutlu Ozkan, Emel; Guven, Deniz Can; Erman, Mustafa; Karahan, Latif; Sahin, Elif; Karakayali, Anıl; Can Sanci, Pervin; Kefeli, Umut; Cabuk, Devrim; Kolemen, Erdem; Kidi, Mehmet Mutlu; Biter, Sedat; Koseci, Tolga; Urun, Muslih; Mermit Ercek, Berrak; Bayir, Duygu; Agdas, Gözde; Sakalar, Teoman; Majidova, Nargiz; Yildiz, Sedat; Demir, Hacer; Akosman, Cengiz; Ersoy, Mustafa; Kilickap, Saadettin; Kocaaslan, Erkam; Turkoğlu, Ezgi; Yildirim, Sedat; Arvas, Hayati; Yesil Cinkir, Havva; Apaydin Rollas, Aslihan Ezgi

Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

C-PLAN 指数在接受免疫治疗的非小细胞肺癌患者中的预后意义

Nuransoy Cengiz, Ayse; Bozkurt, Oktay; Cengiz, Muhammet; Ozkan, Metin; Inanc, Mevlude; Kefeli, Umut; Cabuk, Devrim; Erman, Mustafa; Kilickap, Saadettin; Koseci, Tolga; Bayir, Duygu; Guven, Deniz Can; Urun, Muslih; Cosar, Ramazan; Sakalar, Teoman; Majidova, Nargiz; Mutlu Ozkan, Emel; Akosman, Cengiz; Ersoy, Mustafa; Sahin, Elif; Can Sanci, Pervin; Yildiz, Canan; Kolemen, Erdem; Agdas, Gözde; Kocaaslan, Erkam; Turkoğlu, Ezgi; Yildirim, Sedat; Mermit Ercek, Berrak; Karakayali, Anıl; Arvas, Hayati; Kidi, Mehmet Mutlu; Biter, Sedat; Yesil Cinkir, Havva; Karahan, Latif; Apaydin Rollas, Aslihan Ezgi

Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy

对 EMPOWER-Lung 1 研究中接受 cemiplimab 治疗与化疗治疗的晚期非小细胞肺癌患者的患者报告结局进行回顾

Gandara, David R; Gümüş, Mahmut; Kilickap, Saadettin; Sezer, Ahmet; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; Yan, Eric; Jia, Xue; Kim, Eric; Seebach, Frank; Quek, Ruben G W

Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

接受免疫检查点抑制剂治疗的长期生存者的健康相关生活质量和心理社会结局:一项全国多中心研究

Sahin, Taha Koray; Atalah, Fatih; Koylu, Bahadir; Oruc, Ahmet; Acarbay, Aydin; Karakok, Akgun; Dogan, Sevgi; Kikili, Cevat Ilteris; Turhan, Görkem; Emin, Gamze; Celik, Selahattin; Deliktas Onur, Ilknur; Tuzcu, Tuba Ugur; Biter, Sedat; Efil, Safa Can; Ardic, Fadime Sinem; Gokmen, Azer; Guzel, Halil Goksel; Turan, Kadri; Disli, Ahmet Kürsad; Tunbekici, Salih; Goker, Erdem; Inanc, Mevlude; Ozdemir, Ozlem; Ozturk, Banu; Urun, Muslih; Yasar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Kara, Ismail Oguz; Sutcuoglu, Osman; Ates, Ozturk; Eren, Tulay; Yildirim, Atila; Kilickap, Saadettin; Dizdar, Omer; Turker, Fatma Alev; Erman, Mustafa; Artac, Mehmet; Selcukbiricik, Fatih; Aksoy, Sercan; Guven, Deniz Can

Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50

Cemiplimab 单药治疗作为一线治疗方案,用于治疗程序性死亡配体 1 (PD-L1) ≥50 的晚期非小细胞肺癌脑转移患者。

Kilickap, Saadettin; Özgüroğlu, Mustafa; Sezer, Ahmet; Gümüş, Mahmut; Bondarenko, Igor; Gogishvili, Miranda; Turk, Haci M; Cicin, Irfan; Bentsion, Dmitry; Gladkov, Oleg; Sriuranpong, Virote; Quek, Ruben G W; McIntyre, Debra A G; He, Xuanyao; McGinniss, Jennifer; Seebach, Frank; Gullo, Giuseppe; Rietschel, Petra; Pouliot, Jean-Francois

Very deep prostate-specific antigen decline is associated with longer rPFS in patients with metastatic castration-sensitive prostate cancer

前列腺特异性抗原水平的深度下降与转移性去势敏感性前列腺癌患者的更长无进展生存期相关。

Kapar, Caner; Gulturk, Ilkay; Tugcu, Volkan; Sahin, Selçuk; Guler, Haydar; Kilickap, Saadettin; Tural, Deniz

Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

免疫疗法与化疗治疗晚期胸膜间皮瘤的疗效比较:一项土耳其肿瘤协作组(TOG)研究

Kalkan, Ziya; Ebinc, Senar; Arcagok, Murat; Bilici, Ahmet; Yildiz, Ozcan; Kilickap, Saadettin; Guven, Deniz Can; Tatli, Ali Murat; Sumbul, Ahmet Taner; Mandel, Nil Molinas; Ozturk, Akin; Bardakci, Murat; Karakaya, Serdar; Kaplan, Muhammet Ali

Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina 2025, 61, 638

更正:Kalkan 等人,《免疫疗法与化疗治疗晚期胸膜间皮瘤的疗效:一项土耳其肿瘤协作组 (TOG) 研究》,Medicina 2025, 61, 638

Kalkan, Ziya; Ebinc, Senar; Arcagok, Murat; Bilici, Ahmet; Yildiz, Ozcan; Kilickap, Saadettin; Guven, Deniz Can; Tatli, Ali Murat; Sumbul, Ahmet Taner; Mandel, Nil Molinas; Ozturk, Akin; Bardakci, Murat; Karakaya, Serdar; Kaplan, Muhammet Ali

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

恩曲替尼治疗 ROS1 阳性晚期非小细胞肺癌:BFAST II/III 期试验

Peters, Solange; Gadgeel, Shirish M; Mok, Tony; Nadal, Ernest; Kilickap, Saadettin; Swalduz, Aurélie; Cadranel, Jacques; Sugawara, Shunichi; Chiu, Chao-Hua; Yu, Chong-Jen; Moskovitz, Mor; Tanaka, Tomohiro; Nersesian, Rhea; Shagan, Sarah M; Maclennan, Margaret; Mathisen, Michael; Bhagawati-Prasad, Vijay; Diarra, Cheick; Assaf, Zoe June; Archer, Venice; Dziadziuszko, Rafal